Exploring Cannabis Neuroprotective Benefits in Older Adults
Recent research highlights cannabis neuroprotective benefits older adults might experience, challenging traditional views on cognitive aging. These findings suggest potential brain health support from cannabis in elderly populations. Clinicians should…
Potency-related Effects of Smoked Cannabis on Simulated Driving Performance
Cannabis potency driving impairment significantly affects simulated driving performance, especially with higher THC levels. This dose-dependent effect is crucial for clinicians counseling patients on safe cannabis use. Understanding these risks helps…
Cannabis Regulation Business Trends and Challenges
This article reviews cannabis regulation business trends impacting clinical practice. It highlights legal uncertainty and the rise of minor cannabinoid products. Understanding cannabis regulation business challenges is key for clinicians and patients…
The Cannabis Mental Health Evidence Gap: Association vs. Causation
The cannabis mental health evidence gap highlights the challenges in distinguishing association from causation in cognitive decline studies. Current research shows no clear link between cannabis use and dementia risk in older adults. Clinicians must…
Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I
The DEA has placed 2-Methyl AP-237, a synthetic opioid, into Schedule I due to its high abuse potential. This synthetic opioid scheduling reflects federal efforts to control emerging drugs rapidly. Clinicians should monitor these developments for…
Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I
The scheduling of novel synthetic opioids such as butonitazene, flunitazene, and metodesnitazene in Schedule I highlights their high abuse potential. This regulatory update aids clinicians in recognizing these substances with no accepted medical use.…
Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I
The schedules of controlled substances placement by the DEA now include etodesnitazene, N-pyrrolidino etonitazene, and protonitazene in Schedule I. These synthetic opioid analogs have high abuse potential and no accepted medical use. Clinicians should be…
Understanding Firearms Regulatory Guidance in the Cannabis Context
Firearms regulatory guidance cannabis issues present complex challenges for clinicians. Understanding the legal conflicts between federal firearms laws and state cannabis regulations is essential. This guidance helps ensure patient safety and proper…
Clinical Implications of Marijuana Rescheduling
Marijuana rescheduling clinical implications are significant for research and medical practice. Rescheduling to Schedule III reduces barriers for clinical studies and may improve patient access. Clinicians should stay informed about evolving regulations…
Someones gotta do it!
Someone has to conduct the rigorous clinical trials, and it turns out that responsibility comes with surprisingly thorough documentation requirements. The peer review process is significantly less forgiving than most institutional review boards. Via…
